Online inquiry

IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2516MR)

This product GTTS-WQ2516MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CALCRL gene. The antibody can be applied in Migraine research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001271751.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10203
UniProt ID Q16602
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2516MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11637MR IVTScrip™ mRNA-Anti-LAG3&PDCD1, MGD-013(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MGD-013
GTTS-WQ14538MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ1374MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABT-874
GTTS-WQ10091MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ15499MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ3764MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ9487MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IPH-5401
GTTS-WQ3011MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-Beta7
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW